

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: MATSUMOTO <i>et al.</i>	Atty. Docket No.: VX062735 PCT
Serial No.: 10/577,135	Group Art Unit: 1623
Filed: April 25, 2006	Examiner: Elli PESELEV
Title: TYROSINASE ACTIVITY INHIBITOR AND AMELIORANT FOR FACIAL BLOOD FLOW	Confirmation No.: 3070

Commissioner for Patents
Alexandria, VA 22314

Date: July 12, 2010

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §1.56, the references listed on the attached Form PTO-1449-PLG are being brought to the attention of the Examiner without any admission that they constitute statutory prior art, or without any admission that they contain subject matter that anticipates the invention or renders the invention obvious to a person of ordinary skill in the art.

Further, pursuant to 37 C.F.R. §1.97(e), the undersigned hereby certifies that the listed reference were first cited in a Communication (English language copy enclosed) from a foreign patent office in connection with a counterpart foreign application not more than three months prior to the filing of this statement. Please note that WO 01/01798 A1 and JP 62-077328 A, two of the references cited in the foreign communication, were already disclosed in the Supplemental Information Disclosure Statement filed on January 16, 2007 and December 8, 2009, respectively.

The Examiner is requested to initial the attached PTO Form-1449-PLG and return a copy of same to the undersigned attorney as proof that the listed references have been considered and made of record.

As a Final Office Action on the merits has been mailed in the above identified application on April 15, 2010, the fee due under 37 CFR 1.17(p) is enclosed. Please charge any additional fee to Applicant's attorney's Deposit Account No. 50-1147.

Respectfully submitted,

/David G. Posz/

David G. Posz
Reg. No. 37,701

Posz Law Group, PLC
12040 South Lakes Drive, Suite 101
Reston, VA 20191
(703) 707-9110
Customer No. 23400